Nutriband CEO Gareth Sheridan Publishes Letter to Shareholders, Outlines 2025 Achievements and 2026 Outlook

Wednesday, Dec 31, 2025 7:01 am ET1min read
NTRB--

Nutriband CEO Gareth Sheridan published a letter to shareholders highlighting achievements and milestones in 2025, including the sale of 90% of its Pocono subsidiary to EarthVision Bio for $5M, a 25% Preferred Stock dividend, and the expiration of warrants from the 2021 IPO on Oct 1, 2026. These moves aim to boost shareholder value and advance the commercialization of its lead product, AVERSA™ Fentanyl, a potential game-changer in the opioid transdermal patch market.

Nutriband CEO Gareth Sheridan Publishes Letter to Shareholders, Outlines 2025 Achievements and 2026 Outlook

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet